Dernières nouvelles pour GrowGeneration (NASDAQ:GRWG) Stock

GrowGeneration

GrowGeneration Corp owns and operates specialty retail hydroponic and organic gardening stores. The firm is a marketer and distributor of nutrients, growing media, indoor and greenhouse lighting, ventilation systems and accessories for hydroponic gardening. The Company has two reportable segments, including Cultivation and Gardening segment, composed of the Company's hydroponic and organic gardening business; and the Storage Solutions segment, composed of the Company's benching, racking, and storage solutions business.

GrowGeneration Corp

News

CORRECTION: V2X Ticker Is 'VVX'

Ascendiant Capital analyst Edward Woo maintains Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) with a Buy and raises the price target from $7.5 to $9.

Price Target

Analyst Ratings

DUOT

Ascendiant Capital Maintains Buy on Duos Technologies Group, Raises Price Target to $9

Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer presented the ATH434-201 Phase 2 clinical trial results at the annual MSA Research Symposium hosted by University College London, Institute of Neurology in partnership with the MSA Trust of the U.K.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Presents Phase 2 Results for Neurodegenerative Disease Treatment

D. Boral Capital analyst Jason Kolbert initiates coverage on Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) with a Buy rating and announces Price Target of $10.

Initiation

CODX

D. Boral Capital Initiates Coverage On Co-Diagnostics with Buy Rating, Announces Price Target of $10

In the <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">changing landscape of global trade</a>, Kansas farmers are setting their sights on an old grain with a new vision. Sorghum, long regarded mainly as livestock feed, is being rebranded as the next superfood as growers race to acquire new buyers.
What Happened: China was once the top buyer of Sorghum, but it cancelled major purchases in January in anticipation of tariffs, according to the Wall Street Journal. As a result, storage facilities in Kansas are overflowing.
Speaking <a href="https://www.wsj.com/business/move-over-quinoa-theres-a-new-it-crop-in-town-7e371e42?mod=business_lead_pos2">to</a> the WSJ, Kim Barnes, CFO of Pawnee County Cooperative, said "I just kept turning over rocks and boulders until I found a place to go with it." He sold his stock to ethanol plants and feed businesses, incurring a loss.
Kansas produces most of the country's sorghum, but only a small portion is used for food. Promoters of the grain hope to change that. "We do see sorghum as kind of that ‘it' crop for domestic food," said Adam York, head of Kansas Sorghum Producers.
See Also: <a href="https://www.benzinga.com/25/04/45033064/16-million-chinese-jobs-under-threat-amid-escalating-us-china-trade-war-predicts-goldman-sachs">16 Million Jobs At Risk In China As US Tariffs Hammer Manufacturing And Retail Sectors, Goldman Sachs Warns</a>
Why It Matters: Despite its benefits, sorghum has a long way to go, because many see it primary as cattle feed. "Because so many of us were raised on farms, there is that barrier," said dietitian Missy Schrader to the WSJ. 
Despite challenges, chef George Duran is optimistic. "If we could just market it as maybe, like, ‘The Miracle Grain' or something, I think it can really go pretty far," he said.
Sorghum is the latest addition to the list of grains that have been touted as superfoods of the future. Last year, Microsoft co-founder Bill Gates spotlighted Fonio, a lesser-known African grain, as a game-changer that can serve as a vital staple in its native regions and also emerge as a potential solution to <a href="https://www.benzinga.com/news/24/04/38508127/bill-gates-says-americans-are-obsessed-with-wheat-and-corn-but-this-lost-grain-from-africa-is-the-fu">global food sustainability challenges</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45031287/us-companies-earn-6x-more-in-china-than-they-export-heres-why-blowing-up-global-trade-would-be-economic-suicidesays-leading-fund-manager">S&amp;P 500 Companies Earn 6x More In China Than US Exports: Hedge Fund Manager Says Trade War With Beijing Level Of Stupidity That Has &#8216;No Precedent&#8217;</a></li>
</ul>
Image Via Shutterstock

Health Care

General

Kansas Farmers Push Sorghum As The Next Superfood Amid Trade War Strains And Surging Stockpiles

HALO

Halozyme Announces argenx Received A Positive CHMP Opinion Recommending EC Approval Of VYVGART 1000mg Developed With VYVGART 1000mg For Chronic Inflammatory Demyelinating Polyneuropathy

V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) Inc., has been awarded a $103 million contract by the U.S. Navy for Contractor Logistics Support (CLS) maintenance of C-26 aircraft, reinforcing V2X's role as the best-value provider for this critical mission.
Under this contract, V2X will continue providing comprehensive CLS support, including aircraft engineering, upgrades maintenance and modifications.
"This award highlights the Navy's continued confidence in V2X's proven ability to deliver mission-capable aircraft with exceptional performance," said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. "With a longstanding history of supporting Navy aviation, this contract reaffirms our commitment to providing mission-ready aircraft that enhance operational readiness worldwide."
"With readiness rates north of 90%, V2X consistently delivers mission-capable aircraft while managing all aspects of maintenance, personnel, and equipment," said Vinny Caputo, Senior Vice President of Aerospace Systems at V2X. "A key&nbsp;differentiator in V2X's offering is our numerous FAA Part 145 repair stations, which are readiness multipliers," Caputo added.&nbsp;
Work for this firm-fixed-price contract is expected to begin in June 2025, supporting eight C-26A/D aircraft stationed at four main operating bases, including one U.S. location and three international sites.

Contracts

V2X Awarded $103M U.S. Navy Contract For C-26 Support

royalty payments on future troriluzole product net sales
<ul>
<li>$250 million to be funded at closing</li>
<li>$150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole</li>
<li>Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expenses</li>
</ul>

BHVN

Biohaven Announces $600M Non-Dilutive Funding Agreement With Oberland Capital To Advance Rare Disease Portfolio

All-new Vanquish Autonomous is designed to improve productivity and profitabilityWAUKESHA, Wis., April 28, 2025 /PRNewswire/ -- Mean Green, a leading battery-powered, commercial-grade turf care manufacturer and a Generac
All-new Vanquish Autonomous is designed to improve productivity and profitability
WAUKESHA, Wis., April 28, 2025 /PRNewswire/ -- Mean Green, a leading battery-powered, commercial-grade turf care manufacturer and a Generac Power Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) company, today announced the expansion of its commercial-grade electric mower lineup with its all-new Vanquish Autonomous.

GNRC

Mean Green Expands Commercial-Grade Electric Mower Lineup With Vanquish Autonomous

British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting positive data from its Phase 2 study of lead product candidate, Bria-IMT&#x2122;, in metastatic breast cancer, and from its preclinical Bria-OTS+ platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. In addition, Phase 3 early biomarker data will be presented as a late breaking abstract.

BCTX

TSX:BCT

BriaCell Showcases Positive Phase 2 Results for Breast Cancer Therapy at Major Cancer Conference

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $25 price target.

URGN

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

Guardforce AI Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>) reported quarterly losses of $(0.53) per share. This is a 88.3 percent increase over losses of $(4.53) per share from the same period last year. The company reported $36.35 million in sales this quarter. This is a 0.18 percent increase over sales of $36.28 million the same period last year.

Earnings

GFAI

Guardforce AI Co FY EPS $(0.53) Up From $(4.53) YoY, Sales $36.35M Up From $36.28M YoY

HSBC analyst Rajesh Kumar downgrades Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) from Buy to Reduce and lowers the price target from $1150 to $700.

Downgrades

HSBC Downgrades Eli Lilly to Reduce, Lowers Price Target to $700

WIIM

OPRA

Opera shares are trading higher after the company announced better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates. Also, the company issued Q2 sales guidance with its midpoint above estimates.

dditional Gene Therapy Technology Expands Genprex's Portfolio of Oncology Licenses
AUSTIN, Texas, April 28, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4413794-1&amp;h=3302239736&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has signed an exclusive patent license agreement with NYU Langone Health related to the drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid). The therapy is under investigation as a potential treatment for mesothelioma. The subject patent is co-owned by Genprex and NYU Langone Health, and the license provides Genprex with patent exclusivity.

Penny Stocks

GNPX

Genprex Signs Exclusive Patent License Agreement With NYU Langone Health Related To Drug Candidate, Reqorsa Gene Therapy

D. Boral Capital analyst Jesse Sobelson maintains Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Buy and maintains $4.5 price target.

VERI

D. Boral Capital Maintains Buy on Veritone, Maintains $4.5 Price Target

CGON

CG Oncology shares are trading higher after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.

The CNN Money Fear and Greed index some decline in market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Friday.
U.S. stocks settled higher on Friday, with the Nasdaq Composite jumping more than 1% during the session. Major indices also recorded gains last week, with the S&amp;P 500 adding 4.6% and the Nasdaq jumping 6.7%. The Dow also notched a weekly gain of 2.5%.
Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) shares gained 1.5% after the company reported better-than-expected results for the first quarter. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares climbed 9.8%, while NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) added 4.3% on Friday.
Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) reported a wider-than-expected loss for the first quarter on Friday.
President Donald Trump claimed to have held a phone call with President Xi Jinping, yet Chinese officials denied that any talks had taken place.
On the economic data front, the University of Michigan consumer sentiment was revised higher to a reading of 52.2 in April versus a preliminary reading of 50.8, and compared to March&#8217;s reading of 57.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, financials and utilities stocks recording biggest losses on Friday. However, consumer discretionary and information technology stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed higher by around 20 points to 40,113.50 on Friday. The S&amp;P 500 jumped 0.74% to 5,525.21, while the Nasdaq Composite surged 1.26% at 17,382.94 during Friday's session.
Investors are awaiting earnings results from Domino&#8217;s Pizza, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>), NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) and Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) today.
At a current reading of 35.3, the index remained in the &#8220;Fear&#8221; zone on Friday, versus a prior reading of 36.9.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based
&nbsp;on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/45007118/top-2-health-care-stocks-that-may-crash-this-month">Top 2 Health Care Stocks That May Crash This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

GOOG

GOOGL

NVDA

NXPI

TSLA

Nasdaq Jumps Over 200 Points, Investor Fear Increases Slightly, But Fear & Greed Index Remains In 'Fear' Zone

Wells Fargo initiates coverage on Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Equal-Weight rating and announces Price Target of $62.

Wells Fargo Initiates Coverage On Zillow Gr with Equal-Weight Rating, Announces Price Target of $62

PRTG: 81% &#x7C; <a href="https://www.benzinga.com//node/45034198">Portage Biotech Reports Confirmatory Preclinical Efficacy Data For PORT-7 (TT-4). The New Data In A Murine Mesothelioma Model Demonstrated Single-Agent Activity For PORT-7 That Was Superior To Treatment With Single-Agent Anti-PD1 Antibody</a>
&nbsp;
AMPY: 34% &#x7C; <a href="https://www.benzinga.com//node/45022800">Amplify Energy shares are trading higher after the company announced its termination of the previously announced merger agreement with Juniper Capital</a>
&nbsp;
RVMD: 7% &#x7C; <a href="https://www.benzinga.com//node/45035501">Revolution Medicines shares are trading higher after the company announced new clinical data for zoldonrasib as monotherapy in patients with KRAS G12D mutant non-small cell lung cancer.</a>

Comments

GrowGeneration

Actualités

Dernières nouvelles pour GrowGeneration (NASDAQ:GRWG) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL